{"date":"2026-01-15","count":13,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6576-2026-01-15-1730-er9sjc","company_id":"6576","company":"逸達","market":"上櫃","industry":"生技醫療","date":"2026-01-15","time":"17:30:13","subject":"本公司美國子公司Foresee USA向美國FDA提出創新藥MMP-12抑制劑Linvemastat (FP-020) 用於治療氣喘之二期臨床試驗申請","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：逸達（6576），2026-01-15 17:30，「本公司美國子公司Foresee USA向美國FDA提出創新藥MMP-12抑制劑Linvemastat (FP-020) 」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7829-2026-01-15-1724-1q5gxxt","company_id":"7829","company":"思捷優達-KY","market":"興櫃","industry":"生技醫療","date":"2026-01-15","time":"17:24:24","subject":"(更正公告)本公司代子公司公告董事任期屆滿全面改選暨董事變動達三分之一","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：思捷優達-KY（7829），2026-01-15 17:24，「(更正公告)本公司代子公司公告董事任期屆滿全面改選暨董事變動達三分之一」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6794-2026-01-15-1705-185i2uo","company_id":"6794","company":"向榮生技","market":"上市","industry":"生技醫療","date":"2026-01-15","time":"17:05:01","subject":"公告本公司法人董事因分割移轉股份而由分割受讓公司接續原法人董事職務(更新114/11/28重訊)","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：向榮生技（6794），2026-01-15 17:05，「公告本公司法人董事因分割移轉股份而由分割受讓公司接續原法人董事職務(更新114/11/28重訊)」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6796-2026-01-15-1702-11vxjjv","company_id":"6796","company":"晉弘","market":"上市","industry":"生技醫療","date":"2026-01-15","time":"17:02:51","subject":"本公司114年現金增資股款催繳公告","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：晉弘（6796），2026-01-15 17:02，「本公司114年現金增資股款催繳公告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6467-2026-01-15-1607-1u6pvow","company_id":"6467","company":"泰合","market":"興櫃","industry":"生技醫療","date":"2026-01-15","time":"16:07:35","subject":"公告本公司取得經濟部產業發展署出具「係屬科技事業且具市場性」之意見書","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：泰合（6467），2026-01-15 16:07，「公告本公司取得經濟部產業發展署出具「係屬科技事業且具市場性」之意見書」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7829-2026-01-15-1604-6mh3w9","company_id":"7829","company":"思捷優達-KY","market":"興櫃","industry":"生技醫療","date":"2026-01-15","time":"16:04:11","subject":"公告本公司董事會決議增資子公司案","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：思捷優達-KY（7829），2026-01-15 16:04，「公告本公司董事會決議增資子公司案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7829-2026-01-15-1603-1u8b6es","company_id":"7829","company":"思捷優達-KY","market":"興櫃","industry":"生技醫療","date":"2026-01-15","time":"16:03:48","subject":"本公司代子公司公告現金增資案","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：思捷優達-KY（7829），2026-01-15 16:03，「本公司代子公司公告現金增資案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7829-2026-01-15-1603-1qwmgqy","company_id":"7829","company":"思捷優達-KY","market":"興櫃","industry":"生技醫療","date":"2026-01-15","time":"16:03:29","subject":"本公司代子公司公告董事任期屆滿全面改選","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：思捷優達-KY（7829），2026-01-15 16:03，「本公司代子公司公告董事任期屆滿全面改選」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4131-2026-01-15-1557-je3k7e","company_id":"4131","company":"浩泰","market":"上櫃","industry":"生技醫療","date":"2026-01-15","time":"15:57:04","subject":"代子公司八億實業股份有限公司公告董事會決議召開115年度第二次股東臨時會","clause":"第17款","fact_date":"2026-01-15","cite_as":"公開資訊觀測站重大訊息：浩泰（4131），2026-01-15 15:57，「代子公司八億實業股份有限公司公告董事會決議召開115年度第二次股東臨時會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4131-2026-01-15-1556-cva609","company_id":"4131","company":"浩泰","market":"上櫃","industry":"生技醫療","date":"2026-01-15","time":"15:56:45","subject":"代子公司八億實業股份有限公司公告董事異動暨董事變動達三分之一","clause":"第6款","fact_date":"2026-01-15","cite_as":"公開資訊觀測站重大訊息：浩泰（4131），2026-01-15 15:56，「代子公司八億實業股份有限公司公告董事異動暨董事變動達三分之一」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4131-2026-01-15-1556-17wvck","company_id":"4131","company":"浩泰","market":"上櫃","industry":"生技醫療","date":"2026-01-15","time":"15:56:20","subject":"代子公司八億實業股份有限公司公告董事會決議通過解除經理人競業禁止案","clause":"第21款","fact_date":"2026-01-15","cite_as":"公開資訊觀測站重大訊息：浩泰（4131），2026-01-15 15:56，「代子公司八億實業股份有限公司公告董事會決議通過解除經理人競業禁止案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4131-2026-01-15-1555-fecgna","company_id":"4131","company":"浩泰","market":"上櫃","industry":"生技醫療","date":"2026-01-15","time":"15:55:56","subject":"代子公司八億實業股份有限公司公告總經理異動","clause":"第6款","fact_date":"2026-01-15","cite_as":"公開資訊觀測站重大訊息：浩泰（4131），2026-01-15 15:55，「代子公司八億實業股份有限公司公告總經理異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4117-2026-01-15-1417-1ge0eyf","company_id":"4117","company":"普生","market":"興櫃","industry":"生技醫療","date":"2026-01-15","time":"14:17:32","subject":"本公司依公開發行公司資金貸與及背書保證處理準則第二十五條第一項第三款規定公告","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：普生（4117），2026-01-15 14:17，「本公司依公開發行公司資金貸與及背書保證處理準則第二十五條第一項第三款規定公告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}